Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + cyclophosphamide + vincristine + prednisone + interferon
- Development stage
- Unknown
- Lead developer
- IDEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular
01
Overview
This is a multi-agent combination regimen consisting of the monoclonal antibody rituximab (anti-CD20), the alkylating agent cyclophosphamide, the vinca alkaloid vincristine (Oncovin), the corticosteroid prednisone, and an interferon (typically interferon-alpha). The regimen is used primarily in hematologic malignancies such as follicular lymphoma. Rituximab targets CD20 on B-cells leading to cell lysis; cyclophosphamide crosslinks DNA causing apoptosis; vincristine inhibits microtubule formation disrupting mitosis; prednisone induces apoptosis in lymphoid cells and has anti-inflammatory effects; and interferons have antiproliferative and immunomodulatory actions. This combination aims to maximize antitumor efficacy by targeting cancer cells through multiple mechanisms[2][3].
- Other names
- rituximab, cyclophosphamide, vincristine, prednisone, and interferon combination therapy
02
Targets
CD20 (B-lymphocyte antigen CD20)IFNAR (Immune system modulation via type I interferon receptor)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + cyclophosphamide + vincristine + prednisone + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + cyclophosphamide + vincristine + prednisone + interferon.